MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

Bromfenac sodium

CAS No. : 91714-93-1

MCE 国际站：Bromfenac sodium

产品活性：Bromfenac sodium 是一种强效且具有口服活性的 COX 抑制剂，对 COX-1 和 COX-2 的 IC₅₀ 分别为 5.56 和 7.45 nM。Bromfenac sodium 可用于眼部炎症研究。

研究领域：Immunology/Inflammation

作用靶点：COX

In Vitro: Bromfenac (0-80 μg/mL; 24 h) can inhibit transforming growth factor-β2-induced epithelial-mesenchymal transition in HLEC-B3 in a concentration-dependent manner.
Bromfenac (80 μg/Ml; 48 h) inhibits transforming growth factor-β2-induced epithelial-mesenchymal transition in human anterior capsules.

In Vivo: Bromfenac (0.0032-3.16%; 100 or 200 μL; rubbed onto the backs) produces significant anti-inflammatory activity at concentrations as low as 0.1% (4 h pretreatment time) or 0.32% (18 h pretreatment time) in rats.
Bromfenac (0.032-3.16%; 100 μL; rubbed onto the paws) produces dose-related anti-inflammatory activity in rats.
Bromfenac (0.032-1.0%; 50 μL) is 26 times more potent than indomethacin in blocking the erythema when applied directly onto the skin area exposed to UV light in guinea pigs.
Bromfenac (0.0032-0.1%; 50 μL; rubbed onto the uninjected paw for 4 h per day and 5 days per week) produces a dose and time dependent reduction in the paw volume of both hind limbs in rats.
Bromfenac (0.32%; 50 μL; rubbed onto the abdomen) produces significant blockade of abdominal constriction to ACh challenge in mice.
Bromfenac (eyedrop instillation; 1 μL (0.09%) per eye; twice-daily; 4 w) partially reduces corneal staining, and becomes so more slowly by the 4-week time point.

相关产品：Drug Repurposing Compound Library Plus  |  FDA-Approved Drug Library Plus  |  FDA-Approved Drug Library Mini  |  Bioactive Compound Library Plus  |  Anti-Infection Compound Library  |  Immunology/Inflammation Compound Library  |  FDA-Approved Drug Library  |  Anti-Aging Compound Library  |  Drug Repurposing Compound Library  |  NMPA-Approved Drug Library  |  Pyroptosis Compound Library  |  Orally Active Compound Library  |  FDA Approved & Pharmacopeial Drug Library  |  Drug-Induced Liver Injury (DILI) Compound Library  |  Anti-Pancreatic Cancer Compound Library  |  Mechanoreceptors Compound Library  |  Anti-Colorectal Cancer Compound Library   |  Antidepressant Compound Library  |  EMA-Approved Drug Library  |  Human Metabolite Library  |  Anti-Prostate Cancer Compound Library  |  Non-steroidal Anti-Inflammatory Compound Library  |  Off-patent Drug Library  |  Meloxicam-d₃-1  |  4-Methylamino antipyrine hydrochloride  |  Vedaprofen-d₃  |  Pelubiprofen-¹³C,d₃  |  N-tert-Butyl-α-phenylnitrone-d₁₄  |  Tepoxalin  |  Ampyrone  |  Pectolinarigenin  |  Ermanin  |  Aceclofenac-d₄  |  SC-58125  |  Salicylic acid-¹³C₆  |  (±)-Naproxen-d₃-1  |  Dehydroevodiamine hydrochloride  |  Aspirin-d₄  |  Asaraldehyde  |  Broussonin E  |  (-)-Epicatechin  |  COX-2/15-LOX-IN-1  |  20(S)-Ginsenoside Rg3  |  Ginsenoside Rd  |  Salicylic acid-d₆  |  TFAP  |  Hydrangenol  |  Alminoprofen  |  Acetaminophen-d₃  |  FPL 62064  |  Crocin II  |  AG-024322  |  Ketoprofen-¹³C,d₃

热门产品线：重组蛋白  |  化合物库  |  天然产物  |  荧光染料  |  PROTAC  |  同位素标记物  |  寡核苷酸  |  抗体  |  点击化学

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Fluorescent Dye  |  PROTAC  |  Isotope-Labeled Compounds  |  Oligonucleotides  |  Antibodies  |  Click Chemistry

货号: HY-B1888A

品牌介绍:
•   MCE (MedChemExpress) 拥有200 多种全球独家化合物库，我们致力于为全球科研客户提供前沿最全的高品质小分子活性化合物；
•   50,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领；
•   产品种类涵盖各种重组蛋白，多肽，常用试剂盒 ，更有 PROTAC、ADC 等特色产品，广泛应用于新药研发、生命科学等科研项目；
•   提供虚拟筛选，离子通道筛选，代谢组学分析检测分析，药物筛选等专业技术服务；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种顶级期刊及制药专利收录了MCE客户的科研成果；
•   专业团队跟踪最新的制药及生命科学研究进展，为您提供全球最新的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。